Automating the Path to Parenthood: Why We're Leading Conceivable's $50M Series A

When Joshua Abram, Alan Murray, and Alejandro Chávez-Badiola, the co-founders of Conceivable, walked into our offices, they posed a simple question: "Do you expect the IVF process to be automated in 20 years?"

We said "Yes, of course."

"We agree," they responded. "But we know we can pull that forward to today."

That conversation crystallizes everything we need to know about Conceivable. These founders aren't content to wait for the future – they're determined to build it now. And in a field where one in six couples worldwide struggle to conceive, where demand outstrips capacity by more than 10x, and where the journey to parenthood can feel impossibly isolating, their urgency makes perfect sense.

The Problem Hidden in Plain Sight

Walk into any IVF lab today and you'll witness a paradox. Here, in spaces dedicated to creating life through cutting-edge science, embryologists perform delicate single-cell procedures as they manipulate some of the smallest cells in the human body using techniques that remain largely manual.

This manual reality creates a cascade of challenges. Labs can't scale to meet demand. Success rates vary wildly between facilities. Costs remain prohibitively high. The skilled embryologist workforce simply can't grow fast enough to serve the millions who need help. It's a bottleneck that affects real families making one of life's most important journeys.

Joshua, Alan, and Alejandro see this differently than most. Where others see an intractable human expertise problem, they see an automation opportunity waiting to happen.

Conceivable’s Vision: Fully Automated IVF

What strikes us most about this team isn't just their vision – it's their complementary ability to execute on it. Joshua and Alan have been business partners for over two decades, having built and scaled companies including Integral Ad Science (now public on NASDAQ) and TWRM Life Sciences, the world's first automated cryostorage platform for embryos. They understand both the business of scaling complex technologies and the specific nuances of the fertility space.

Alejandro brings something equally crucial: deep clinical credibility. As a reproductive endocrinologist directing one of Mexico's foremost fertility clinics and a leading researcher in IVF automation, he bridges the gap between ambitious technology and clinical reality. This isn't a team that needs to learn the industry – they're already helping shape it.

The energy they bring to every conversation is infectious. They aren't just building a company; they're architecting what they see as the most important paradigm shift in fertility care for the coming generation.

AURA: Reimagining the IVF Lab from First Principles

Conceivable's platform, AURA, doesn't just automate individual steps – it reimagines the entire IVF lab workflow. By combining robotics with AI-driven imaging and remote operation capabilities, AURA handles everything from egg preparation through sperm injection, embryo culture, and cryopreservation.

The outcomes from early patients are already matching those of the world's top fertility centers, while simultaneously expanding clinic capacity.

For fertility clinics, this transforms everything. Instead of managing complex workflows across dozens of manual steps for multiple patients, they can now:

• Standardize processes

• Expand patient access

• Enhance quality control through data-driven oversight

• Free up reproductive endocrinologists to spend more time where they're needed most – with the patients

A Market Crying Out for Transformation

The numbers tell only part of the story. Yes, the global IVF services market represents nearly $20 billion annually. Yes, only about 500,000 IVF babies are born each year compared to an estimated 20 million who could benefit. And yes, IVF volumes are projected to double over the next decade.

But behind these statistics are millions of would-be parents facing an impossible equation: treatments they desperately need but can't access or afford. As fertility networks consolidate and insurance coverage expands, the industry is actively seeking scalable solutions. The timing for automation isn't just right – it's overdue.

Why This Investment Embodies Everything We Believe

At AVP, we back exceptional founders solving tough challenges that take time to get right. Conceivable sits perfectly at the intersection of two areas where we've developed deep conviction: healthcare democratization and vertical-specific robotics.

In healthcare, we consistently invest in companies that expand access while lowering costs – from Boulder Care in addiction treatment to Midi in menopause care. Conceivable represents a step-function change in making quality fertility care accessible to those who need it.

Honoring a Vision That Will Live On

On August 5, 2025– the very day we closed this Series A financing– Joshua Abram passed away from multiple myeloma. We’re grateful for the time we spent with him and the vision he helped shape. His conviction that IVF automation shouldn’t be some distant future but a present reality continues to drive everything Conceivable does.

We’re energized to work with Alan, Alejandro, and the entire Conceivable team to realize Joshua’s vision. They’re not just building better infrastructure for fertility care – they’re ensuring that access to family-building becomes a standard, not a privilege.

This is why we invest: to partner with founders who don’t just want to improve the status quo but fundamentally reshape it. Conceivable is building the foundational technology for the next generation of fertility care, and we’re proud to lead their journey.

Visit conceivable.life and avp.vc to learn more. The official press release can be found here.